COLL Quote, Financials, Valuation and Earnings

Pfizer has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 2.31%. Collegium Pharmaceutical's return on equity of 31.53% beat Pfizer's return on equity of 8.91%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 52.1%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 36.08%. Given that Collegium Pharmaceutical has higher upside potential than Pfizer, analysts believe Collegium Pharmaceutical is more attractive than Pfizer.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Pfizer quarterly revenues of $17.8B. Collegium Pharmaceutical's net income of $12.5M is lower than Pfizer's net income of $410M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 15.13x while Pfizer's PE ratio is 16.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.81x versus 2.06x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 8.8%. Collegium Pharmaceutical's return on equity of 31.53% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 52.1%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 18.51%. Given that Collegium Pharmaceutical has higher upside potential than Supernus Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Supernus Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.882%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Collegium Pharmaceutical's net income of $12.5M is lower than Supernus Pharmaceuticals's net income of $15.3M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 15.13x while Supernus Pharmaceuticals's PE ratio is 24.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.81x versus 2.77x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 31.35%. Collegium Pharmaceutical's return on equity of 31.53% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 52.1%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.84 which suggests that it could grow by 4.89%. Given that Collegium Pharmaceutical has higher upside potential than Vertex Pharmaceuticals, analysts believe Collegium Pharmaceutical is more attractive than Vertex Pharmaceuticals.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Collegium Pharmaceutical's net income of $12.5M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 15.13x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.81x versus 11.17x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 6.89% compared to Collegium Pharmaceutical's net margin of 25.08%. Collegium Pharmaceutical's return on equity of 31.53% beat Zoetis's return on equity of 49.71%.

Collegium Pharmaceutical has a consensus price target of $42.80, signalling upside risk potential of 52.1%. On the other hand Zoetis has an analysts' consensus of $199.87 which suggests that it could grow by 31.73%. Given that Collegium Pharmaceutical has higher upside potential than Zoetis, analysts believe Collegium Pharmaceutical is more attractive than Zoetis.

Collegium Pharmaceutical has a beta of 0.762, which suggesting that the stock is 23.775% less volatile than S&P 500. In comparison Zoetis has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.51%.

Collegium Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.18% to investors and pays a quarterly dividend of $0.50 per share. Collegium Pharmaceutical pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Collegium Pharmaceutical quarterly revenues are $181.9M, which are smaller than Zoetis quarterly revenues of $2.3B. Collegium Pharmaceutical's net income of $12.5M is lower than Zoetis's net income of $581M. Notably, Collegium Pharmaceutical's price-to-earnings ratio is 15.13x while Zoetis's PE ratio is 27.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Collegium Pharmaceutical is 1.81x versus 7.46x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.